In this edition:
Talazoparib + enzalutamide in mCRPC
Final OS in PROpel: abiraterone + olaparib for mCRPC
Rucaparib for mCRPC
SBRT for localised prostate cancer
Plasma miR371 to detect MRD in germ cell tumours
New prognostic factor risk group classification for clinical stage 1 seminoma
89Zr-DFO-girentuximab PET/CT of ccRCC
Immune checkpoint inhibitors in advanced penile SCC
Pembrolizumab for high-risk NMIBC unresponsive to BCG
Extended CheckMate 274 results: nivolumab for high-risk MIUC
Please login below to download this issue (PDF)